Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of HA380 HEMoadsorption in Combination With OXiris Membrane for Continuous HemoDiaFiltration in Patients With Septic Shock - HEMOX-HDF Trial

NCT04997421 is registered in ClinicalTrials.gov with Turku University Hospital as lead sponsor.

NCT NCT04997421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04997421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of HA380 HEMoadsorption in Combination With OXiris Membrane for Continuous HemoDiaFiltration in Patients With Septic Shock - HEMOX-HDF Trial
Lead sponsor
Turku University Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
June 10, 2021
Completion date
December 31, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, septic shock